Alex Goldberg

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) and Amarin Corporation plc (NASDAQ:AMRN) Added to Equity Profile Report's NASDAQ Active Stock Watch List

 
Repost This

Wilmington, DE -- (SBWIRE) -- 07/20/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) and Amarin Corporation plc (NASDAQ:AMRN).

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients closed up in its previous session (+0.10%) on 1,587,961 shares traded after ARIAD Named Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently up (+32.57%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Amarin Corporation plc (NASDAQ:AMRN) a biopharmaceutical company that focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases closed down in its previous session (-2.12%) on 2,547,583 shares traded after Amarin Raised Funds. Amarin Corporation plc (NASDAQ:AMRN) is currently down (-63.99%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Amarin Corporation plc (NASDAQ:AMRN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com